

Beyond the Guidelines

Assessing the Treatment Recommendations of Investigators to Assist in the Practical Management of Multiple Myeloma and Non-Hodgkin Lymphoma

CME INFORMATION

TARGET AUDIENCE

This activity is intended for hematologists, medical oncologists and other healthcare providers involved in the treatment of hematologic cancer.

OVERVIEW OF ACTIVITY

Currently more than 45 drug products are labeled for use in the management of hematologic cancer with more than 55 distinct FDA-approved indications. Although this extensive list of available treatment options is reassuring for patients and oncology professionals, it poses a challenge to the practicing clinician who must maintain up-to-date knowledge of appropriate clinical management strategies across a vast spectrum of tumor types.

Practicing oncologists and their patients regularly turn to clinical investigators at academic and tertiary care centers for advice, answers and second opinions as they attempt to make the often complex and difficult clinical decisions they are confronting. In this capacity and through their roles as trusted educators, counselors and adjudicators, these experts observe patterns, develop insights and gain experiences that in totality represent a treasure trove of information that remains largely untapped. This activity will assist in the development of up-to-date clinical management strategies for multiple myeloma (MM) and non-Hodgkin lymphoma (NHL) that will be useful to hematologists, medical oncologists and other healthcare providers in the clinic.

LEARNING OBJECTIVES

- Appraise recent data on therapeutic advances and changing practice standards in MM and NHL, including chronic lymphocytic leukemia (CLL), and integrate this information, where appropriate, into current clinical care.
- Use available research evidence to guide the selection of cytotoxic and/or biologic regimens for patients with newly diagnosed and relapsed/refractory CLL.
- Develop an algorithm for the risk-stratified induction treatment of patients with follicular lymphoma, diffuse large B-cell lymphoma and mantle-cell lymphoma.

- Recognize the role of novel agents in the management of peripheral T-cell lymphoma and/or advanced-stage cutaneous T-cell lymphoma, and ensure appropriate supportive care measures to minimize side effects.
- Compare and contrast the benefits and risks of immunomodulatory agents, proteasome inhibitors or both as systemic treatment for active MM.
- Identify patients with MM who may benefit from maintenance systemic treatment in both the post-transplant and nontransplant settings.
- Recall new data with investigational agents demonstrating promising activity in NHL and MM.
- Assess the ongoing clinical trials evaluating innovative investigational approaches for NHL and MM, and refer appropriate patients for study participation.

ACCREDITATION STATEMENT

Research To Practice is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

CREDIT DESIGNATION STATEMENT

Research To Practice designates this enduring material for a maximum of 2.75 *AMA PRA Category 1 Credits™*. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

HOW TO USE THIS CME ACTIVITY

This CME activity consists of a video component. To receive credit, the participant should watch the video, complete the Post-test with a score of 70% or better and fill out the Educational Assessment and Credit Form located at ResearchToPractice.com/ASCOHem13/CME.

CONTENT VALIDATION AND DISCLOSURES

Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education. We assess potential conflicts of interest with faculty, planners and managers of CME activities. Real or

apparent conflicts of interest are identified and resolved through a conflict of interest resolution process. In addition, all activity content is reviewed by both a member of the RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.

FACULTY — The following faculty (and their spouses/partners) reported real or apparent conflicts of interest, which have been resolved through a conflict of interest resolution process:

Nathan H Fowler, MD

Co-Director of Clinical and Translational Research
Lead, Phase I and Indolent Research Groups
Department of Lymphoma/Myeloma
The University of Texas MD Anderson Cancer Center
Houston, Texas

Advisory Committee: Celgene Corporation, Roche Laboratories Inc, Spectrum Pharmaceuticals Inc; **Contracted Research:** Celgene Corporation, Novartis Pharmaceuticals Corporation, Roche Laboratories Inc.

Kenneth C Anderson, MD

Kraft Family Professor of Medicine
Harvard Medical School
Director, Jerome Lipper Multiple Myeloma Center
Director, LeBow Institute for Myeloma Therapeutics
Dana-Farber Cancer Institute
Boston, Massachusetts

Advisory Committee: Bristol-Myers Squibb Company, Celgene Corporation, Gilead Sciences Inc, Onyx Pharmaceuticals Inc, Sanofi; **Other Remunerated Activities:** Acetylon Pharmaceuticals Inc.

John P Leonard, MD

Richard T Silver Distinguished Professor of Hematology and Medical Oncology
Associate Dean for Clinical Research
Weill Cornell Medical College
New York, New York

Consulting Agreements: Biotest Pharmaceuticals Corporation, Celgene Corporation, Genentech BioOncology, Gilead Sciences Inc, GlaxoSmithKline, Hospira Inc, Johnson & Johnson Pharmaceuticals, MedImmune Inc, Millennium: The Takeda Oncology Company, Onyx Pharmaceuticals Inc, Pharmacyclics Inc, Sanofi, Seattle Genetics, Spectrum Pharmaceuticals Inc, Teva Oncology.

Robert Z Orlowski, MD, PhD

Director, Myeloma Section
Professor of Medicine
Departments of Lymphoma/Myeloma and
Experimental Therapeutics
Division of Cancer Medicine
The University of Texas MD Anderson Cancer Center
Houston, Texas

Advisory Committee: Abbott Laboratories, Array BioPharma Inc, Bristol-Myers Squibb Company, Celgene Corporation, Genentech BioOncology, Millennium: The Takeda Oncology Company; **Contracted Research:** Celgene Corporation, Millennium: The Takeda Oncology Company, Onyx Pharmaceuticals Inc.

Owen A O'Connor, MD, PhD

Professor of Medicine and Developmental Therapeutics
Director, Center for Lymphoid Malignancies
Columbia University Medical Center
College of Physicians and Surgeons
NewYork-Presbyterian Hospital
New York, New York

Advisory Committee: Allos Therapeutics, Millennium: The Takeda Oncology Company, Mundipharma International Limited, Onyx Pharmaceuticals Inc, Spectrum Pharmaceuticals Inc; **Consulting Agreements:** Bristol-Myers Squibb Company, Celgene Corporation, Millennium: The Takeda Oncology Company.

Sonali M Smith, MD

Associate Professor
Section of Hematology/Oncology
Director, Lymphoma Program
The University of Chicago
Chicago, Illinois

Advisory Committee: Allos Therapeutics, Amgen Inc, Celgene Corporation, Genentech BioOncology, Onyx Pharmaceuticals Inc, Seattle Genetics.

MODERATOR — Dr Love is president and CEO of Research To Practice, which receives funds in the form of educational grants to develop CME activities from the following commercial interests: AbbVie Inc, Algeta US, Allos Therapeutics, Amgen Inc, ArQule Inc, Astellas, Aveo Pharmaceuticals, Bayer HealthCare Pharmaceuticals, Biodesix Inc, Biogen Idec, Boehringer Ingelheim Pharmaceuticals Inc, Bristol-Myers Squibb Company, Celgene Corporation, Daiichi Sankyo Inc, Dendreon Corporation, Eisai Inc, EMD Serono Inc, Foundation Medicine Inc, Genentech BioOncology, Genomic Health Inc, Gilead Sciences Inc, Incyte Corporation, Lilly USA LLC, Medivation Inc, Merck, Millennium: The Takeda Oncology Company, Mundipharma International Limited, Novartis Pharmaceuticals Corporation, Onyx Pharmaceuticals Inc, Prometheus Laboratories Inc, Regeneron Pharmaceuticals, Sanofi, Seattle Genetics, Spectrum Pharmaceuticals Inc and Teva Oncology.

RESEARCH TO PRACTICE STAFF AND EXTERNAL

REVIEWERS — The scientific staff and reviewers for Research To Practice have no real or apparent conflicts of interest to disclose.

This educational activity contains discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for

each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the publisher or grantors.

This activity is supported by educational grants from Celgene Corporation, Genentech BioOncology/Biogen Idec, Millennium: The Takeda Oncology Company, Onyx Pharmaceuticals Inc and Teva Oncology.

Hardware/Software Requirements:

A high-speed Internet connection
A monitor set to 1280 x 1024 pixels or more
Internet Explorer 7 or later, Firefox 3.0 or later, Chrome, Safari 3.0 or later
Adobe Flash Player 10.2 plug-in or later
Adobe Acrobat Reader
(Optional) Sound card and speakers for audio

Last review date: August 2013

Expiration date: August 2014

SELECT PUBLICATIONS

Fowler

Federico M et al. **R-CVP versus R-CHOP versus R-FM for the initial treatment of patients with advanced-stage follicular lymphoma: Results of the FOLLO5 trial conducted by the Fondazione Italiana Linfomi.** *J Clin Oncol* 2013;31(19):1506-13.

Federico M et al. **R-CVP vs R-CHOP vs R-FM for the initial treatment of patients with advanced stage follicular lymphoma. Preliminary results of FOLLO5 IIL trial.** 11th International Conference on Malignant Lymphoma 2011; **Abstract 135.**

Flinn IW et al. **An open-label, randomized study of bendamustine and rituximab (BR) compared with rituximab, cyclophosphamide, vincristine, and prednisone (R-CVP) or rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) in first-line treatment of patients with advanced indolent non-Hodgkin's lymphoma (NHL) or mantle cell lymphoma (MCL): The Bright study.** *Proc ASH* 2012; **Abstract 902.**

Fowler NH et al. **Lenalidomide and rituximab for untreated indolent lymphoma: Final results of a Phase II study.** *Proc ASH* 2012; **Abstract 901.**

Rummel MJ et al. **Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: An open-label, multicentre, randomised, phase 3 non-inferiority trial.** *Lancet* 2013;381(9873):1203-10.

Salles G et al. **Rituximab maintenance for 2 years in patients with high tumour burden follicular lymphoma responding to rituximab plus chemotherapy (PRIMA): A phase 3, randomised controlled trial.** *Lancet* 2011;377(9759):42-51.

Anderson

Barlogie B et al. **Ninety percent sustained complete response (CR) rate projected 4 years after onset of CR in gene expression profiling (GEP)-defined low-risk multiple myeloma (MM) treated with total therapy 3 (TT3): Basis for GEP-risk-adapted TT4 and TT5.** *Proc ASH* 2008; **Abstract 162.**

Demo SD et al. **Antitumor activity of PR-171, a novel irreversible inhibitor of the proteasome.** *Cancer Res* 2007;67(13):6383-91.

Jakubowiak AJ et al. **A phase 1/2 study of carfilzomib in combination with lenalidomide and low-dose dexamethasone as a frontline treatment for multiple myeloma.** *Blood* 2012;120(9):1801-9.

Kirk CJ et al. **The selective proteasome inhibitor carfilzomib is well tolerated in experimental animals with dose intensive administration.** *Proc ASH* 2008; **Abstract 2765.**

Korde N et al. **Phase II clinical and correlative study of carfilzomib, lenalidomide, and dexamethasone (CRd) in newly diagnosed multiple myeloma (MM) patients.** *Proc ASH* 2012; **Abstract 732.**

Kumar SK et al. **Risk of progression and survival in multiple myeloma relapsing after therapy with IMiDs and bortezomib: A multicenter International Myeloma Working Group study.** *Leukemia* 2011;26(1):149-57.

Kumar S et al. **Novel three- and four-drug combination regimens of bortezomib, dexamethasone, cyclophosphamide, and lenalidomide, for previously untreated multiple myeloma: Results from the multi-center, randomized, phase 2 EVOLUTION study.** *Proc ASH* 2010; **Abstract 621.**

Kumar S et al. **Novel three- and four-drug combinations of bortezomib, dexamethasone, cyclophosphamide, and lenalidomide, for newly diagnosed multiple myeloma: Encouraging results from the multi-center, randomized, phase 2 EVOLUTION study.** *Proc ASH* 2009; **Abstract 127.**

Richardson PG et al. **Lenalidomide, bortezomib, and dexamethasone combination therapy in patients with newly diagnosed multiple myeloma.** *Blood* 2010;116(5):679-86.

Sonneveld P et al. **HOVON-65/GMMG-HD4 randomized phase III trial comparing bortezomib, doxorubicin, dexamethasone (PAD) vs VAD followed by high-dose melphalan (HDM) and maintenance with bortezomib or thalidomide in patients with newly diagnosed multiple myeloma (MM).** *Proc ASH* 2010; **Abstract 40.**

Spencer A et al. **Consolidation therapy with low-dose thalidomide and prednisolone prolongs the survival of multiple myeloma patients undergoing a single autologous stem-cell transplantation procedure.** *J Clin Oncol* 2009;27(11):1788-93.

Stewart AK et al. **How I treat multiple myeloma in younger patients.** *Blood* 2009;114(27):5436-43.

Leonard

Byrd J et al. **The Bruton's tyrosine kinase (BTK) inhibitor ibrutinib (PCI-32765) promotes high response rate, durable remissions, and is tolerable in treatment naïve (TN) and relapsed or refractory (RR) chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) patients including patients with high-risk (HR) disease: New and updated results of 116 patients in a Phase Ib/II study.** *Proc ASH 2012*;Abstract 189.

Mossner E et al. **Increasing the efficacy of CD20 antibody therapy through the engineering of a new type II anti-CD20 antibody with enhanced direct and immune effector cell-mediated B-cell cytotoxicity.** *Blood 2010*;115(22):4393-402.

Stevenson FK et al. **B-cell receptor signaling in chronic lymphocytic leukemia.** *Blood 2011*;118(16):4313-20.

Van Meerten T, Hagenbeek A. **CD20-targeted therapy: A breakthrough in the treatment of non-Hodgkin's lymphoma.** *Neth J Med 2009*;67(7):251-9.

Orlowski

Dimopoulos MA et al. **Pomalidomide in combination with low-dose dexamethasone: Demonstrates a significant progression free survival and overall survival advantage, in relapsed/refractory multiple myeloma (MM): A Phase III, multicenter, randomized, open-label study.** *Proc ASH 2012*;Abstract LBA-6.

Fostier K et al. **Carfilzomib: A novel treatment in relapsed and refractory multiple myeloma.** *Onco Targets Ther 2012*;5:237-44.

Kumar S et al. **Weekly MLN9708, an investigational oral proteasome inhibitor in relapsed/refractory multiple myeloma (MM): Results from a Phase I study after full enrollment.** *Proc ASCO 2013*;Abstract 8514.

Kumar SK et al. **Risk of progression and survival in multiple myeloma relapsing after therapy with IMiDs and bortezomib: A multicenter International Myeloma Working Group study.** *Leukemia 2012*;26(1):149-57.

Lendvai N et al. **Phase II study of infusional carfilzomib in patients with relapsed or refractory multiple myeloma.** *Proc ASH 2012*;Abstract 947.

Love N et al. **Medical oncologists' clinical experiences and comfort levels with 20 recently approved agents.** *Proc ASCO 2013*;Abstract e17570.

Plesner T et al. **Daratumumab, a CD38 monoclonal antibody in patients with multiple myeloma — Data from a dose-escalation phase I/II study.** *Proc ASH 2012*;Abstract 73.

Shah J et al. **A multi-center Phase I/II trial of carfilzomib and pomalidomide with dexamethasone (Car-Pom-d) in patients with relapsed/refractory multiple myeloma.** *Proc ASH 2012*;Abstract 74.

Shah JJ et al. **The novel KSP inhibitor ARRY-520 is active both with and without low-dose dexamethasone in patients with multiple myeloma refractory to bortezomib and lenalidomide: Results from a phase 2 study.** *Proc ASH 2012*;Abstract 449.

Vij R et al. **Pomalidomide (POM) with or without low-dose dexamethasone (LoDEX) in patients (pts) with relapsed/refractory multiple myeloma (RRMM): Outcomes in pts refractory to lenalidomide (LEN) and/or bortezomib (BORT).** *Proc ASCO 2012*;Abstract 8016.

O'Connor

Advani RH et al. **Brentuximab vedotin (SGN-35) in patients with relapsed or refractory systemic anaplastic large cell lymphoma: A Phase 2 study update.** *Proc ASH 2011*;Abstract 443.

Chiappella A et al. **Rituximab-CHOP21 plus lenalidomide (LR-CHOP21) is effective and feasible in elderly untreated diffuse large B-cell lymphoma (DLBCL): Results of Phase II REAL07 study of the Fondazione Italiana Linfomi (FIL).** *Proc ASH 2012*;Abstract 903.

Coiffier B et al. **Results from a pivotal, open-label, phase II study of romidepsin in relapsed or refractory peripheral T-cell lymphoma after prior systemic therapy.** *J Clin Oncol 2012*;30(6):631-6.

D'Amore F et al. **Up-front autologous stem-cell transplantation in peripheral T-cell lymphoma: NLG-T-01.** *J Clin Oncol 2012*;30(25):3093-9.

Horwitz S et al. **Second-line therapy with ICE followed by high dose therapy and autologous stem cell transplantation for relapsed/refractory peripheral T-cell lymphomas: Minimal benefit when analyzed by intent to treat.** *Proc ASH 2005*;Abstract 2679.

O'Connor O et al. **Phase III study of investigational MLN8237 (alisertib) versus investigator's choice in patients (pts) with relapsed/refractory (rel/ref) peripheral T-cell lymphoma (PTCL).** *Proc ASCO 2012*;Abstract TPS8110.

O'Connor OA et al. **Pralatrexate in patients with relapsed or refractory peripheral T-cell lymphoma: Results from the pivotal PROPEL study.** *J Clin Oncol 2011*;29(9):1182-9.

Reimer P et al. **Autologous stem-cell transplantation as first-line therapy in peripheral T-cell lymphomas: Results of a prospective multicenter study.** *J Clin Oncol* 2009;27(1):106-13.

Schmitz N et al. **Treatment and prognosis of mature T-cell and NK-cell lymphoma: An analysis of patients with T-cell lymphoma treated in studies of German High-Grade Non-Hodgkin Lymphoma Study Group.** *Blood* 2010;116(18):3418-25.

Smith

Alizadeh AA et al. **Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling.** *Nature* 2000;403(6769):503-11.

Hernandez-Ilizaliturri FJ et al. **Higher response to lenalidomide in relapsed/refractory diffuse large B-cell lymphoma in nongerminal center B-cell-like than in germinal center B-cell-like phenotype.** *Cancer* 2011;117(22):5058-66.

Kluin-Nelemans HC et al. **Treatment of older patients with mantle-cell lymphoma.** *N Engl J Med* 2012;367(6):520-31.

Lenz G, Staudt LM. **Aggressive lymphomas.** *N Engl J Med* 2010;362(15):1417-29.

Lenz G et al. **Immunochemotherapy with rituximab and cyclophosphamide, doxorubicin, vincristine, and prednisone significantly improves response and time to treatment failure, but not long-term outcome in patients with previously untreated mantle cell lymphoma: Results of a prospective randomized trial of the German Low Grade Lymphoma Study Group (GLSG).** *J Clin Oncol* 2005;23(9):1984-92.

Nowakowski GS et al. **Combination of lenalidomide with R-CHOP (R2CHOP) is well tolerated and effective as initial therapy for aggressive B-cell lymphomas — A Phase III study.** *Proc ASH* 2012; **Abstract 689.**

Nowakowski GS et al. **Lenalidomide can be safely combined with R-CHOP (R2CHOP) in the initial chemotherapy for aggressive B-cell lymphomas: Phase I study.** *Leukemia* 2011;25(12):1877-81.

Ruan J et al. **Bortezomib plus CHOP-rituximab for previously untreated diffuse large B-cell lymphoma and mantle cell lymphoma.** *J Clin Oncol* 2011;29(6):690-7.

Rummel MJ et al. **Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: An open-label, multicentre, randomised, phase 3 non-inferiority trial.** *Lancet* 2013;381(9873):1203-10.

Rummel MJ et al. **Bendamustine plus rituximab (B-R) versus CHOP plus rituximab (CHOP-R) as first-line treatment in patients with indolent and mantle cell lymphomas (MCL): Updated results from the StiL NHL1 study.** *Proc ASCO* 2012; **Abstract 3.**

Smith MR et al. **Phase II study of rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone immunochemotherapy followed by yttrium-90-ibritumomab tiuxetan in untreated mantle-cell lymphoma: Eastern Cooperative Oncology Group Study E1499.** *J Clin Oncol* 2012;30(25):3119-26.

Wiernik PH et al. **Lenalidomide monotherapy in relapsed or refractory aggressive non-Hodgkin's lymphoma.** *J Clin Oncol* 2008;26(30):4952-7.

Witzig TE et al. **An international phase II trial of single-agent lenalidomide for relapsed or refractory aggressive B-cell non-Hodgkin's lymphoma.** *Ann Oncol* 2011;22(7):1622-7.